Suzanne McGurn, the Executive Officer of the Ontario Public Drug Programs, issued a statement on behalf of the Pan Canadian Pharmaceutical Alliance (pCPA), on February 16, 2016 detailing the end of negotiations with manufacturer Alexion for the listing of Soliris.
Please see the following article for more information.
17
Feb2016
12
Feb2016
As part of the National Prescription Drug Utilization Information System (NPDUIS), the Patented Medicine Prices Review Board (PMPRB) has recently released a report entitled, Generics360 – Generic Drugs in Canada, 2014.
Through this newly named report series, the PMPRB monitors and reports on:
the latest developments in generic drug pricing and markets ... Read More
12
Feb2016
Since Québec is now participating in the pan-Canadian Pharmaceutical Alliance (pCPA), INESSS recently communicated that information sharing has now become necessary to ensure greater efficiency when conducting drug reviews.
As of February 15, 2016, a supplementary document, supporting authorization of information sharing with pCPA, must accompany any drug submission application pertaining ... Read More
25
Nov2015
PDCI has developed considerable expertise assisting manufacturers with product listing agreements(PLAs) through the pan-Canadian Pharmaceutical Alliance (pCPA), with individual provinces (including Quebec) and with private payers. With the formalization of the pCPA process and private payers moving aggressively into the PLA environment (see PDCIs white paper), PDCI is growing ... Read More
03
Nov2015
On Friday, October 30, 2015 PDCI presented a webinar entitled “Market Access Climate Change: the Evolving Impact of Product Listing Agreements”.
The purpose of this webinar was to:
Shed light on the recent developments at the pCPA; and
Enhance the understanding of the growing practice of PLA negotiations in the private payer ... Read More
20
Oct2015
Interested in learning more about new developments at the pan-Canadian Pharmaceutical Alliance (pCPA)?
Curious to know more about private payer Product Listing Agreements (PLAs) in Canada?
PDCI Market Access (PDCI) is hosting a free webinar on Friday, October 30, 2015 from 11:00 AM -12:00 PM EDT titled Market Access Climate Change: the ... Read More
16
Oct2015
In a recent update released on their website, the pan-Canadian Pharmaceutical Alliance (pCPA) announced two significant developments:
Québec is now participating in the pCPA; and
The Office of the pCPA (the Office) is now operational.
In Fall 2014, the Provincial/Territorial Health Ministers announced intentions for Québec’s participation in the Federation’s Health Care ... Read More
23
Feb2015
Effective February 9, 2015 and until this process is transitioned to the pan-Canadian Pharmaceutical Alliance (pCPA) office, Saskatchewan will serve as the single point of entry for the pan-Canadian generic price tier confirmation process. The Saskatchewan Drug Plan will verify that the Tiered Pricing Framework applies to the ... Read More
09
Feb2015
PDCI Market Access Inc. interviewed a representative from one of the pan-Canadian Pharmaceutical Alliance (pCPA) lead provinces and has produced an article providing guidance for negotiating with the pCPA. The pCPA has completed approximately 50 negotiations since it was established in 2010, but stakeholders are still looking for greater transparency ... Read More
16
Oct2014
Pan-Canadian Pharmaceutical Alliance (pCPA) has posted the IBM Report on its website
The much anticipated IBM report (entitled “Pan Canadian Drugs Negotiation Report”) has now been posted on the pCPA website.
The objectives of the IBM engagement include:
Recommending options for the development of a permanent model that will facilitate negotiations for brand ... Read More